Jun 20, 2024
Following FDA Approval to Commence the Clinical Trial, an Official Site Initiation Has Taken Place as Preparation for Patient Enrollment Advances Multiple Robotic Systems Already Received by the Site to Allow Inventory Readiness in Support of Trial BRAINTREE, Mass.
Jun 17, 2024
The Site Initiation Visit for the BWH clinical staff is complete and a shipment of LIBERTY investigational units was delivered BRAINTREE, Mass. , June 17, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announces that Brigham and Women’s Hospital (BWH), a leading academic
Jun 04, 2024
HINGHAM, Mass. , June 04, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 1,566,669 shares of the Company’s common stock at a
Jun 03, 2024
HINGHAM, Mass. , June 03, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 1,566,669 shares of the Company’s common stock at a purchase price of $1.50 per share of common stock in a registered
Jun 03, 2024
The trial will be conducted in the U.S. and its results will complement the preclinical data on the LIBERTY® Endovascular Robotic Surgical System, which together are expected to support a future 510(k) submission BRAINTREE, Mass. , June 03, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc.
Apr 29, 2024
The next step of the collaboration will explore potential future applications of the LIBERTY system, including its potential capabilities for remote endovascular procedures BRAINTREE, Mass. , April 29, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative
Apr 15, 2024
All Regulatory, Clinical, Operational and Pre-Commercial Activities Continue to Stay on Track Despite the On-going Situation in Israel Company Believes that Both Regulatory and Commercial Milestones to be Achieved in Accordance with the Company’s Current Timeline BRAINTREE, Mass.
Feb 05, 2024
The Investigational Device Exemption (IDE) application follows the completion of multiple activities necessary to file this application BRAINTREE, Mass. , Feb. 05, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the LIBERTY ® Endovascular Robotic Surgical System,
Jan 30, 2024
All of the cash payable to the plaintiffs in the settlement will be covered by Microbot’s insurance carrier and will not impact company's cash position BRAINTREE, Mass. , Jan. 30, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular

Displaying 1 - 9 of 154

Search Investor Relations